Esperion Therapeutics Inc (NASDAQ:ESPR) major shareholder Boxer Capital, Llc sold 100,000 shares of the company’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $56.38, for a total transaction of $5,638,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Boxer Capital, Llc also recently made the following trade(s):
- On Friday, November 2nd, Boxer Capital, Llc sold 40,000 shares of Esperion Therapeutics stock. The stock was sold at an average price of $55.21, for a total transaction of $2,208,400.00.
Shares of Esperion Therapeutics stock opened at $58.80 on Wednesday. Esperion Therapeutics Inc has a fifty-two week low of $33.06 and a fifty-two week high of $82.68. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -8.42 and a beta of 2.20.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.22). During the same quarter in the previous year, the company earned ($1.86) EPS. On average, equities research analysts predict that Esperion Therapeutics Inc will post -6.31 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB acquired a new stake in Esperion Therapeutics in the 1st quarter valued at about $250,000. Keybank National Association OH boosted its stake in Esperion Therapeutics by 97.7% during the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 3,787 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Esperion Therapeutics by 40.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 2,224 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in Esperion Therapeutics in the second quarter valued at approximately $333,000. Finally, Creative Planning lifted its stake in Esperion Therapeutics by 42.0% in the third quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 2,236 shares in the last quarter.
Several analysts recently issued reports on ESPR shares. Stifel Nicolaus started coverage on shares of Esperion Therapeutics in a report on Friday, September 14th. They set a “buy” rating and a $89.00 price objective for the company. Citigroup raised shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $57.00 to $75.00 in a report on Friday, August 17th. Zacks Investment Research raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a report on Wednesday, October 3rd. BTIG Research started coverage on shares of Esperion Therapeutics in a report on Tuesday, October 16th. They set a “buy” rating and a $82.00 price objective for the company. Finally, BidaskClub downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 22nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Esperion Therapeutics currently has a consensus rating of “Buy” and an average target price of $75.96.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://macondaily.com/2018/11/07/boxer-capital-llc-sells-100000-shares-of-esperion-therapeutics-inc-espr-stock.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: Marijuana Stocks
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.